The present study was designed to evaluate the antimutagenic potential of flavonoid of Kigelia africana leaves, using micronucleus and chromosomal aberration assay in mouse bone marrow. The antimutagenic effect of flavonoid of Kigelia africana leaves was assessed using cyclophosphamide induced micronuclei (MN) formation and chromosomal aberration (CA) in mouse. The animals were pre-treated with the flavonoid of Kigelia africana given orally (p.o.) at two test doses of 100 & 200 mg/kg body weight for 7 days. In MN test the two doses provided protection when given 24 h prior to a single i.p. administration of 100mg /kg body weight of cyclophosphamide and the efficacy of the test doses were compared with the control group. In CA assay the two doses provided protection when given 24 hours prior to a single ip administration (100mg/kg body weight) of cyclophosphamide followed by a single ip administration of colchicine (4mg/kg body weight), 90 minutes before cell harvesting and efficacy of the test doses were compared with that of the control group. The percentage protection was increased in a dose dependent manner. These results demonstrate that flavonoid of Kigelia africana has got antimutagenic potential.

To study the antitumor effect of Kigelia Africana. Antitumor activity of methanolic extracts of 100, 200 mg/kg of Kigelia Africana leaves was evaluated against Ehrlich ascites carcinoma (EAC) tumor induced in to mammary glands of mice. Acute and short-term toxicity studies were performed initially in order to ascertain the safety of methanolic extracts of Kigelia Africana. After 12 days of tumor inoculation, the extract was administered daily for 30 days. The effect of methanolic extracts of Kigelia Africanaon the growth of tumor, life span of EAC bearing hosts and simultaneous alterations in the haematological profile and histopathological profile were estimated. The methanolic extracts of Kigelia Africana showed decrease in tumor size, average body weight, mean survival time thereby increasing life span of EAC tumor bearing mice. Haematological profile reverted to more or less normal levels in extracts treated mice. Histopathology has minimal effects when compared but a significant variation is seen.

To study the antitumor effect of Kigelia africana. Antitumor activity of methanolic extracts of 100, 200 mg/kg of Kigelia Africana leaves was evaluated against Ehrlich ascites carcinoma (EAC) tumor in mice. Acute and short-term toxicity studies were performed initially in order to ascertain the safety of methanolic extracts of Kigelia Africana. After 12 days of tumor inoculation, the extract was administered daily for 30 days. The effect of methanolic extracts of Kigelia Africana on the growth of tumor, life span of EAC bearing hosts and simultaneous alterations in the haematological profile and histopathological profile were estimated. The methanolic extracts of Kigelia africana showed decrease in tumor size, average body weight, mean survival time thereby increasing life span of EAC tumor bearing mice. Haematological profile reverted to more or less normal levels in extracts treated mice. Histopathology has minimal effects when compared but a significant variation is seen.